Skip to content

Blue California Presents New Clinical Findings on Ergothioneine at NUTRITION 2024

Dr May-Zhang at ASN

Rancho Santa Margarita, CA (July 09, 2024) — Blue California presented results from a human clinical trial evaluating ErgoActive® L-ergothioneine supplementation in older adults at NUTRITION 2024, the annual meeting of the American Society for Nutrition, held in Chicago.

Dr May-Zhang at ASNDr. Linda May-Zhang, Vice President of Science and Innovation at Blue California, presented the research, which was sponsored by Blue California and conducted independently by Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO).

What did the ergothioneine clinical trial study?

The 16-week randomized, double-blind, placebo-controlled trial included 147 adults aged 55 to 79 who reported subjective memory concerns but did not have dementia. Participants received one of the following daily interventions:

  • 10 mg of ErgoActive® L-ergothioneine
  • 25 mg of ErgoActive® L-ergothioneine
  • Placebo

The study evaluated composite memory as its primary outcome. Additional assessments included other cognitive domains, subjective memory, sleep quality, plasma ergothioneine concentrations, blood biomarkers, leukocyte telomere length, and safety.

What were the main findings?

Daily supplementation produced substantial, dose-dependent increases in plasma ergothioneine, confirming that ErgoActive® was effectively absorbed. Plasma levels increased approximately three- to six-fold in the 10 mg group and six- to sixteen-fold in the 25 mg group at weeks 4 and 16.

The 25 mg group showed an improvement in composite memory at week 4 within the treatment group. Subjective prospective memory and sleep initiation also improved in a dose-dependent manner, with statistically significant effects observed at 25 mg.

ErgoActive® was safe and well tolerated at both doses. Because participants began the study with slightly above-average cognitive performance and relatively high baseline ergothioneine concentrations, additional studies in people with lower baseline cognitive function or ergothioneine status may help clarify who is most likely to benefit.

“This study helps advance our understanding of ergothioneine supplementation in healthy older adults,” said Dr. May-Zhang. “The dose-ranging design allowed us to examine not only cognitive and sleep-related outcomes, but also the absorption and safety of two daily doses of ErgoActive®.”

Ergothioneine is a naturally occurring, diet-derived amino acid antioxidant found most abundantly in mushrooms. Interest in ergothioneine has grown because humans have a dedicated transporter, OCTN1/ETT, that absorbs and distributes it to tissues throughout the body.

Publication update (updated July 2025)

The complete study was published in 2025 in the peer-reviewed journal Nutraceuticals:

Zajac IT, Kakoschke N, Kuhn-Sherlock B, May-Zhang LS. “The Effect of Ergothioneine Supplementation on Cognitive Function, Memory, and Sleep in Older Adults with Subjective Memory Complaints: A Randomized Placebo-Controlled Trial.” Nutraceuticals. 2025;5(3):15. https://doi.org/10.3390/nutraceuticals5030015

Learn more about ErgoActive® L-ergothioneine and its applications in healthy aging, cognitive health, food, beverage, and dietary-supplement formulations.